Onchocerciasis
Conditions
Sponsors
Higher Institute of Scientific and Medical Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Treatment phase 1.1. Moxidectin arm - Age = 4 years - Resident in the study area for at least one year - to give informed consent 1.2. Ivermectin arm - Age = 5 years - Resident in the study area for at least one year - to give informed consent 2. Epidemiological evaluation in each arm - Age = 4 years - Resident of the study area - Complete the questionnaire - Ability to give informed consent
Exclusion criteria
Exclusion criteria: - Pregnant women as determined by self-declaration or confirmed by a rapid urine pregnancy test. - Individuals with a known history of allergy or hypersensitivity to ivermectin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the prevalence of O. volvulus skin microfilaridermia;Reduction in the seroprevalence of Ov16 antibodies among children under 10 years of age;Reduction in the density of O. volvulus skin microfilaridermia;Viability of adult female O. volvulus worms;Increase in therapeutic coverages | — |
Secondary
| Measure | Time frame |
|---|---|
| Projected time to interruption of onchocerciasis transmission under different treatment regimens | — |
Countries
Cameroon
Contacts
Public ContactGuy Wafeu Sadeu
Higher Institute of Scientific and Medical Research
Outcome results
None listed